According to Renub Research latest report, “Switzerland Diabetes Market, Size, Forecast 2023-2028, By SMBG Device, Continuous Glucose Monitoring (CGM), Insulin Pen, Insulin Pump, and Company Analysis” the Switzerland Diabetes Market is estimated to reach US$ 4.69 billion by 2028. In Switzerland, almost half a million people are affected by diabetes. Diabetes is a chronic disease when the pancreas does not produce too much sugar. It is a significant reason for blindness, kidney failure, heart attacks, stroke, and lower limb amputation. Moreover rising aging population, quantitative and qualitative changes in diet plan, the prevalence and cost of diabetes in Switzerland and an increase in the number of diabetic patients has significantly driven the market of diabetes in Switzerland. According to World Health Organisation, in 2020, Diabetes Mellitus Deaths in Switzerland was 1,022 of total death.

In Switzerland, an aging population, an unhealthy diet, and diabetic people affect approximately 5% of the population; type 2 diabetes, the most common type affects about 500,000 people, while type 1 diabetes affects about 40,000 people, according to the Swiss medical net. Also, Type -1 diabetes is proliferating in Switzerland among teenagers and children. In fact, Health insurance is mandatory in Switzerland, and the primary benefit package is the same in the entire country. However, yearly total health care costs (Swiss Francs (CHF) exchanged to Euro (EUR); of diabetes patients were obtained from providers’ claims and defined as the total payments made by the mandatory health insurance for outpatient and inpatient services per patient and year. 

Expert Insights: Ask Analyst or Download Full Report with TOC & Figures: https://www.renub.com/switzerland-diabetes-market-p.php

Although, In Switzerland – as in many cardiovascular diseases have been the most common cause of death for decades. Around one-third of all deaths are traceable to cardiovascular diseases, and this proportion rises with increasing age. More and more people in Switzerland suffer from cardiovascular disease, diabetes, or several diseases simultaneously. Increases the consumption of resources. Development poses a significant challenge concerning controllable parameters for healthcare provision in our country and should be tackled resolutely. Costs from the outpatient setting comprised fees for office-based physician visits, hospital outpatient visits, paramedical visits, nursing homes, medications, laboratory tests, and medical devices. 

Insulin Pen creates more demand in Switzerland Diabetes Market

 The rising aging population, urbanization, unbalanced diet, excess consumption of alcohol, and increasing R&D activity will boost the demand for Insulin pens in Switzerland’s Diabetes Market. However, Insulin pen needles are often used with a pen injector device for the subcutaneous injection of insulin. They are commonly used by people with diabetes who often require multiple daily insulin injections.

 SMBG, Insulin Pump, and CMG will also capture the largest share of the market. The rising population of diabetic patients, lack of physical activity, unhealthy diet, rising awareness regarding the benefits of using these devices, and increasing per capita disposable income boost the demand of Switzerland’s Diabetes Market. However, 95% of the insulin used in Switzerland is sold in a concentration of 40 units per ml (U-40 insulin). The Insulin Pump is especially suitable for patients with type-1 diabetes who require a continuous supply of insulin and need to balance every meal with additional insulin in Switzerland.

Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=switzerland-diabetes-market-p.php

Competitive Landscape

 Switzerland Diabetes companies include B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickenson (BD), Novo Nordisk A/S, Ypsomed AG, Medtronic, Insulet Corporation, Abbott Laboratories, DarioHealth Corp., Dexcom Inc., Roche Diagnostic, and Tandem Diabetes Care.

• IN Nov 2020, Eli Lilly and Company and Ypsomedannounced a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly’s connected diabetes solutions. 

 Device – We have covered by device in the Switzerland Diabetes Market breakup by 4 viewpoints (SMBG, CGM, Insulin Pen and Insulin Pump)

 All the key players have been covered from 3 Viewpoints (Overview, Recent Development, and Revenue Analysis) (B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickenson (BD), Novo Nordisk A/S, Ypsomed AG, Medtronic, Insulet Corporation, Abbott Laboratories, DarioHealth Corp., Dexcom Inc., Roche Diagnostic, and Tandem Diabetes Care)

About the Company: 

Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.

Media Contact:

Company Name: Renub Research

Contact Person: Rajat Gupta, Marketing Manager

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Address: 225 Kristie Ln, Roswell, GA 30076

Email: info@renub.com

LinkedIn: https://in.linkedin.com/company/renub-research

Web: www.renub.com

Thanks https://buddynews.co.uk/